Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Redx Pharma Plc RNS Release

Holding(s) in Company

RNS Number : 4030Y
Redx Pharma plc
02 March 2017
 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi



1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached:
ii

Redx Pharma Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached


An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments


An event changing the breakdown of voting rights


Other (please specify):

CHANGE TO THE TOTAL NUMBER OF VOTING RIGHTS IN ISSUE FOLLOWING RECENT OPEN OFFER

3. Full name of person(s) subject to the notification obligation: iii

Aviva plc & its subsidiaries    

4. Full name of shareholder(s)
 (if different from 3.):iv

Registered Holder:

Chase (GA Group) Nominees Limited
7,594,762*

HSBC Global Custody Nominee (UK) Limited
2,221,267*

State Street Nominees Limited
301,856*

                                                             

*denotes direct interest

 

Chase (GA Group) Nominees Limited
270,741

 

Chase Nominees Limited
256,190

 

5. Date of the transaction and date on which the threshold is crossed or reached: v

1 March 2017

6. Date on which issuer notified:

2 March 2017

7. Threshold(s) that is/are crossed or
reached:
vi, vii

5% to 7% Change at Direct Interest Level

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of
shares


if possible using
the ISIN CODE

Situation previous
to the triggering
transaction

Resulting situation after the triggering transaction

Number
of
Shares

Number
of
Voting
Rights

Number
of shares

Number of voting
rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares


GB00BSNB6S51

6,111,483

6,111,483

10,644,816

10,117,885

526,931

7.999%

0.417%


 

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial
instrument

Expiration
date
xiii

Exercise/
Conversion Period
xiv

Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.

% of voting
rights






 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial
instrument

Exercise price

Expiration date xvii

Exercise/
Conversion period
xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 






Nominal

Delta



 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

10,644,816

8.416%

 

9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable:
xxi

The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-

 

Aviva Investors Global Services Limited:

·      Aviva plc (Parent Company)

·      Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

·      Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

·      Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

 


Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will cease
to hold:


12. Date on which proxy holder will cease to hold
voting rights:


 

 


13. Additional information:

 

Figures are based on a total number of voting rights of 126,477,914 as per the Company's 'Result of General Meeting and Issue of Equity' Announcement of 28 February 2017.

 

14. Contact name:

     Neil Whittaker, Aviva plc

15. Contact telephone number:

     01603 684420

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLBLGDXLUGBGRD



Redx Pharma Plc Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use